UpToDate® Lexidrug™ is a drug information and medication decision-support product that delivers point-of-care drug monographs, dosing guidance for special populations, drug interaction checking, IV compatibility, calculators, patient education handouts, and reference datasets accessible via web and mobile apps.
Published Aug 21, 2026
A KLAS entry for "Wolters Kluwer UpToDate LexiDrug Pro" was located in a KLAS report excerpt that included a reported score but with a limited respondent sample. KLAS scoring can indicate customer satisfaction, but the small sample limits how broadly the result can be generalized without additional context about the surveyed population.
Vendor announcements in late 2025 describe integration of Lexidrug medication information into UpToDate Expert AI and note deployment activity with major health systems. This indicates product direction toward generative-AI–enabled clinical decision support, but it does not constitute independent evidence of clinical impact for LexiDrug Pro as a standalone product.
Best fit tends to be:
Decision makers:
End users:
Get a comprehensive analysis of Wolters Kluwer UpToDate Pro™: UpToDate® Lexidrug™ including market position, competitive landscape, adoption trends, and peer benchmarks.
Download full report →Limited requirements for depth
Strict low-latency Android bedside use
Dependence on competitor-specific modules
Procurement needs requiring publicly accessible product-specific compliance attestations
Budget-constrained individual purchasers
A vendor-hosted testimonial on Wolters Kluwer’s Lexidrug product page quotes a U.S. pharmacist saying the product is thorough and valuable in day-to-day work. Example quote (vendor-hosted; not independently verified):
This is a marketing-provided testimonial and should be interpreted as a user statement provided by the vendor rather than independent verification.
Public community discussions on social platforms and professional forums indicate:
Examples of community sentiment (anecdotal, not independently verified):
Aggregated mobile app store review summaries indicate a large installed base but mixed ratings in some snapshots. Recurring complaints in reviews include:
These usability issues are relevant because Lexidrug is often used in time-sensitive clinical contexts.
Net: community discussion and app-store feedback provided more accessible candid commentary than enterprise-focused review platforms during this research session.
Marketing collateral and solution briefs are available, but independently validated, detailed case studies with transparent methodology are limited in the public materials reviewed.
Vendor materials assert capabilities such as alignment with UpToDate content, enhanced dosing guidance for special populations, and interactive tools to support medication decisions. Where ROI or outcome improvements are implied, the sources reviewed did not provide transparent study methodologies, baseline rates, or third-party audited outcomes.
Good fit when:
Poor fit when:
UpToDate® Lexidrug™ (formerly Lexicomp®) is Wolters Kluwer’s drug information and medication decision-support product. It provides point-of-care drug monographs, dosing guidance (including special populations), drug interaction checking, IV compatibility (Trissel’s), calculators, patient education handouts, and related drug reference datasets via web and mobile app access. It functions as a drug-reference layer intended to complement UpToDate’s disease- and condition-focused clinical decision support content.
Official positioning (vendor statements) includes:
Lexidrug targets:
The vendor positions the product as an evidence-reviewed, expert-edited drug reference intended to offer greater depth than lighter-weight drug apps.